该产品别称为6-Fluoro-3-hydroxypyrazine-2-carboxamide; CAS 259793-96-9; T-705,应用类型为:Neutralize,Favipiravir shows anti-influenza virus activities with IC50 ranged from 0.013 to 0.48 _g/ml for the influenza A viruses, from 0.039 to 0.089 _g/ml for the influenza B viruses, and from 0.030 to 0.057 _g/ml for the influenza C viruses. In mammalian cell lines (MDCK cells, Vero cells, HEL cells, A549 cells, HeLa cells, and HEp-2 cells), Favipiravir shows no cytotoxicity at concentrations up to 1,000 _g/ml. [1] In MDCK cells inoculated with seasonal influenza A (H1N1) viruses, Favipiravir induces lethal mutagenesis. [
产品描述
Fingolimod (FTY720) is a sphingosine 1-phosphate receptor modulator indicated and approved for the treatment of relapsing-remitting multiple sclerosis. Fingolimod (trade name Gilenya, Novartis) is metabolized by sphingosine kinase to the active metabolite, fingolimod-phosphate. Fingolimod-phosphate is a sphingosine 1-phosphate receptor modulator, and binds with high affinity to sphingosine 1-phosphate receptors 1, 3, 4, and 5. Fingolimod-phosphate blocks the capacity of lymphocytes to egress from lymph nodes, reducing the number of lymphocytes in peripheral blood. The mechanism by which fingolimod exerts therapeutic effects in multiple sclerosis is unknown, but may involve reduction of lymphocyte migration into the central nervous system. Fingolimod was approved as a first-in-class, orally active drug for relapsing multiple sclerosis in 2010, and its applications in other disease conditions are currently under clinical trials.
产品形式
干粉;灰白色粉末
保存建议
Store desiccated as supplied at -20°C for up to 2 years. Store solutions at -20°C for up to 1 month. Prevent multiple freeze-thaw cycles.